BDRXBiodexa Pharmaceuticals Plc

Nasdaq midatechpharma.com


$ 0.57 $ -0.01 (-2.17 %)    

Wednesday, 28-Aug-2024 15:59:56 EDT
QQQ $ 468.16 $ -5.41 (-1.13 %)
DIA $ 411.36 $ -1.55 (-0.38 %)
SPY $ 558.32 $ -3.26 (-0.58 %)
TLT $ 97.88 $ -0.12 (-0.12 %)
GLD $ 231.76 $ -1.64 (-0.7 %)
$ 0.5772
$ 0.61 x 100
-- x --
-- - --
$ 0.55 - $ 9.64
125,484
na
137.32M
$ 1.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biodexa-pharmaceuticals-announces-pricing-of-5m-registered-direct-offering-to-sell-an-aggregate-of-5050808-adss-and-278975-pre-funded-warrants-exercisable-for-depositary-shares-at-a-purchase-price-of-094-per-depositary-share-also-announces-concurrent-private-placement

To Sell 5,050,808 American Depositary Shares And 278,975 Pre-Funded Warrants; Proceeds To Fund Development Programs Including $...

 cancer-focused-nano-cap-biodexa-pharmaceuticals-stock-is-surging-on-thursday---heres-why

Biodexa Pharmaceuticals shares surge following phase 2 trial results for eRapa, a potential treatment for Familial Adenomatous ...

 biodexa-pharmaceuticals-reports-12-month-phase-2-trial-results-for-erapa-in-treating-familial-adenomatous-polyposis

17% Median Decrease In Polyp Burden, 75% Non-Progression Rate; Cohort 2 Shows 89% Non-Progressors And 29% Median Polyp Reductio...

 biodexa-pharmaceuticals-reports-phase-1-clinical-data-of-mtx110-in-dmg-brain-cancer-demonstrating-increased-survival-presented-at-ispno-2024

Biodexa Pharmaceuticals PLCPositive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presen...

 biodexa-pharmaceuticals-has-been-granted-us-patent-number-12011445-titled-prevention-of-pancreatic-cell-degeneration-for-the-treatment-of-type-i-diabetes-this-patent-is-licensed-from-melior-pharmaceuticals

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12011445).pn

 biodexa-pharmaceuticals-presents-12-month-phase-2-clinical-trial-results-of-erapa-in-familial-adenomatous-polyposis-to-be-presented-at-the-biennial-insight-2024-meeting

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Bi...

 biodexa-pharmaceuticals-highlights-phase-2-data-results-for-erapa

After the first six months, eRapa appeared to be safe and well-tolerated with a statistically significant 24% reduction (p=0.04...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION